Nicox secures up to €3 million from Kowa to advance NCX 470

Nicox announced that its Japanese partner, Kowa, has received approval to initiate Phase 3 clinical trials of NCX 470, a treatment for ocular hypertension. As a result, Nicox could receive up to €3 million in milestone payments in 2025.

Kowa, responsible for the development of NCX 470 in Japan, will assume all regulatory and commercial costs. This innovative eye drop drug is also in Phase 3 trials in the United States and China, with results expected in the third quarter of 2025.

With these payments, Nicox sees its cash flow horizon extended until the end of 2025. The license agreement could generate royalties ranging from 7% to 12% on net sales in Japan for Nicox.